Progestin treatment induces apoptosis and modulates transforming growth factor-β in the uterine endometrium

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 578-584

  Rodriguez, Gustavo C ^a   Rimel, B J ^a   Watkin, William ^a   Turbov, Jane M ^a   Barry, Cathy ^a   Du, Hongyan ^b   Maxwell, George L ^c   Cline, J M ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Research and Education   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CONJUGATED ESTROGEN; KI 67 ANTIGEN; MEDROXYPROGESTERONE ACETATE; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIAL STROMAL TUMOR; ENDOMETRIUM; FEMALE; IMMUNOHISTOCHEMISTRY; MACACA; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CASPASE 3; FEMALE; KI-67 ANTIGEN; LOGISTIC MODELS; MACACA FASCICULARIS; POSTMENOPAUSE; PROGESTINS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; TRANSFORMING GROWTH FACTOR BETA;

EID: 41549135945     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0551     Document Type: Article

References (77)

1. Amant F, Moerman P, Neven P, Timmerman D, Limbergan E, Vergote I. Endometrial Cancer. Lancet 2005;366:491-505.
2. American Cancer Society. Cancer facts and figures 2006. Atlanta: American Cancer; 2006.
3. Henderson BE, Casagrance JT, Pike MC, et al. The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749-56.
4. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol 1996;143:1195-202.
5. The Writing Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996;275:370-5.
6. Xu W, Xiang Y-B, Zheng W, et al. Weight history and risk of endometrial cancer among Chinese women. Int J Epidemiol 2006;35:159-66.
7. Trentham-Dietz A, Nichols H, Hampton J, Newcomb P. Weight change and risk of endometrial cancer. Int J Epidemiol 2006;35:151-8.
8. Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000;11:185-92.
9. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17β-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002;9:195-207.
10. Webb PM. Commentary: Weight gain, weight loss, and endometrial cancer. Int J Epidemiol 2006;35:166-8.
11. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385-9.
12. Hulka BS, Chambless LE, Kaufman DG, Fowler WC, Greenberg BG. Protection against endometrial carcinoma by combination-product oral contraceptives. J Am Med Assoc 1982;247:475-7.
13. The Cancer and Steroid Hormone (CASH) Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. J Am Med Assoc 1987;257:796-800.
14. The WHO collaborative study of neoplasia and steroid contraceptives. Endometrial cancer and combined oral contraceptives. Int J Epidemiol 1988;17:263-9.
15. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol 1993;82:931-5.
16. Maxwell GL, Schildkraut JM, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 2006;103:535-40.
17. Rosenblatt KA, Thomas DB; WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. Int J Cancer 1991;49:870-4.
18. Benshushan A, Paltiel O, Rojansky N, Brzezinski A, Laufer N. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2002;105:166-9.
19. Tao MH, Xu WH, Zheng W, et al. Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. Int J Cancer 2006;119:2142-7.
20. Orbo A, Rise CE, Mutter G. Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res 2006;66:5613-7.
21. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40.
22. Vereide AB, Kaino T, Sager G, Ørbo A. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2005;97:740-50.
23. Rodriguez GC, Nagarsheth NP, Lee KL, et al. Progestin-induced apoptosis in the macaque ovarian epithelium: differential regulation of transforming growth factor-β. J Natl Cancer Inst 2002;94:50-60.
24. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-8.
25. Whittemore AS, Harris R, Itnyre J; Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Am J Epidemiol 1992;136:1212-20.
26. Kurman RJ, editor. Blaustein's pathology of the female genital tract. 5th ed. New York: Springer-Verlag; 2002.
27. Cline JM, Söderqvist G, Register TC, Williams JK, Adams MR, Von Schoultz B. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. Toxicol Pathol 2001;29:84-90.
28. Brenner RM, Slayden OD. Cyclic changes in the primate oviduct and endometrium. In: Knobil E, Neill JD, editors. The physiology of reproduction. New York (NY): Raven Press; 1994. p. 541-69.
29. Mordenti J. Dosage regimen design for pharmaceutical studies conducted in animals. J Pharm Sci 1986;75:852-7.
30. Yasui T, Uemura H, Tezuka M, Yamada M, Irahara M, Miura M, Aono T. Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res 2001;56:38-44.
31. Cline JM, Söderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998;48:221-9.
32. Conner P, Register TC, Skoog L, Tani E, von Schoultz Cline JM. Expression of p53 and markers for apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys. Am J Obstet Gynecol 2005;193:58-63.
33. Agresti A. An introduction to categorical data analysis. New York: John Wiley & Sons; 1996.
34. Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ, Zheng W. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol 2000;79:169-76.
35. Akcali KC, Khan SA, Moulton BC. Effect of decidualization on the expression of bax and bcl-2 in the rat uterine endometrium. Endocrinology 1996;137:3123-31.
36. Hanifi-Moghaddam, Gielen SC, Kloosterboer HJ, et al. Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone. J Clin Endocrinol Metabol 2005;90:973-83.
37. Wang S, Pudney J, Song J, Mor G, Schwartz PE, Zheng W. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia-precursor of endometrial cancer. Gynecol Oncol 2003;88:108-17.
38. Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM, Johansson E. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod 2001;16:2103-8.
39. Vaskivuo TE, Stenback F, Karhumaa P, Risteli J, Dunkel L, Tapanainen JS. Apoptosis and apoptosis-related proteins in human endometrium. Mol Cell Endocrinol 2000;165:75-83.
40. Reis FM, Ribeiro MF, Maia AL, Spritzer PM. Regulation of human endometrial transforming growth factor β1 and β3 isoforms through menstrual cycle and medroxyprogesterone acetate treatment. Histol Histopathol 2002;17:739-45.
41. Rosario GX, Sachdeva G, Manjramkar DD, Modi DN, Meherji PK, Puri CP. Endometrial expression of immunomodulatory cytokines and their regulators during early pregnancy in bonnet monkeys (Macaca radiata). Hum Reprod 2005;20:3039-46.
42. Okulicz WC, Ace CI, Longcope C, Tast J. Analysis of differential gene regulation in adequate versus inadequate secretory-phase endometrial complementary deoxyribonucleic acid populations from the rhesus monkey. Endocrinology 1996;137:4844-50.
43. Ace CI, Okulicz WC. Differential gene regulation by estrogen and progesterone in the primate endometrium. Mol Cell Endocrinol 1995;115:95-103.
44. Haufel T, Dormann S, Hanusch J, Schwieger A, Bauer G. Three distinct roles for TGF-β during intercellular induction of apoptosis: a review. Anticancer Res 1999;19:105-12.
45. Bursch W, Oberhammer F, Jirtle RL, et al. Transforming growth factor-β1 as a signal for induction of cell death by apoptosis. Br J Cancer 1993;67:531-6.
46. Chiarugi V, Magnelli L, Cinelli M. Complex interplay among apoptosis factors: RB, p53, E2F, TGF-β, cell cycle inhibitors and the bcl2 gene family. Pharmacol Res 1997;35:257-61.
47. Berchuck A, Rodriguez G, Olt GJ, et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β. Am J Obstet Gynecol 1992;166:676-84.
48. Hurteau J, Rodriguez GC, Whitaker RS, et al. Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 1994;74:93-9.
49. Havrilesky LJ, Hurteau JA, Whitaker RS, et al. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β. Cancer Res 1995;55:944-8.
50. Rotello RJ, Lieberman RC, Purchio AF, Gershenson LE. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor 1 in cultured uterine epithelial cells. Proc Natl Acad Sci US A 1991;88:3412-5.
51. El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998;51:149-68.
52. James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 1996;58:395-401.
53. Kyprianou N, Isaacs JT. Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515-22.
54. Roberson KM, Penland SN, Padilla GM, et al. Fenretinide: induction of apoptosis and endogenous transforming growth factor-β in PC-3 prostate cancer cells. Cell Growth Differ 1997;8:101-11.
55. Rendi MH, Suh N, Lamph WW, et al. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor β-dependent apoptosis in breast cancer. Cancer Res 2004;64:3566-71.
56. Mishina Y, Whitworth DJ, Racine C, Behringer RR. High specificity of Müllerian-inhibiting substance signaling in vivo. Endocrinology 1999;140:2084-8.
57. Voutilainen R, Miller WL. Potential relevance of Mullerian-inhibiting substance to ovarian physiology. Semin Reprod Endocrinol 1989;7:88-93.
58. Cate RL, Mattaliano RJ, Hession C, et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986;45:685-98.
59. Byskov AG. Differentiation of mammalian embryonic gonad. Physiol Rev 1986;66:71-117.
60. Masiakos PT, MacLaughlin DT, Maheswaran S, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;11:3488-99.
61. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT. Highly purified Mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 2002;8:2640-6.
62. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK. Endometrial cancer is a receptor-mediated target for Mullerian inhibiting substance. Proc Natl Acad Sci US A 2005;3:111-6.
63. Sporn MB, Roberts AB, Wakefiled LM, Glick AB, Danielpour D. Transforming growth factor β and suppression of carcinogenesis. Princess Takamatsu Symposia 1989;20:259-66.
64. Reiss M. Transforming growth factor-β and cancer: a love-hate relationship? Oncol Res 1997;9:447-57.
65. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor in human disease. N Engl J Med 2000;342:1350-8.
66. Narayan S, Thangasamy T, Balusu R. Transforming growth factor β signaling in cancer. Front Biosci 2005;10:1135-45.
67. Pierce DF Jr, Gorska AE, Chytil A, et al. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc Natl Acad Sci US A 1995;92:4254-8.
68. Tang B, Bottiner E, Bagnall K, Anver M, Wakefield L. Enhanced liver and lung tumorigenesis in TGF-β1 heterozygous knock-out mice following treatment with diethylnitrosamine and phenobarbital [abstract]. Proc Am Assoc Cancer Res 1997;38:584.
69. Lin HK, Bergmann S, Pandolfi PP. Deregulated TGF-Beat signaling in leukemogenesis. Oncogene 2005;24:5693-700.
70. Izzi L, Attisano L. Ubiquitin-dependent regulation of TGF-β signalling in cancer. Neoplasia 2006;8:677-88.
71. Elliot RL, Blobe GC. Role of Transforming Growth Factor β in human cancer. J Clin Oncol 2005;23:2078-93.
72. Kaklamani VG, Pasche B. Role of TGF-β in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 2004;4:649-61.
73. Park SH. Fine tuning and cross-talking of TGF-β signal by inhibitory smads. J Biochem Mol Biol 2005;38:9-16.
74. Sun SY, Hail N, Lotan R. Apoptosis as a novel target for cancer prevention. J Natl Cancer Inst 2004;96:662-72.
75. Ouyang N, Williams JL, Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)δ expression in APC(min/+) mice proportionally to their tumor inhibitory effect: implications for the role of PPARδ in carcinogenesis. Carcinogenesis 2006;27:232-9.
76. Sinicrope FA, Half E, Morris JS, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2004;13:920-7.
77. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999;11:68-75.